11-10　ⓔ文献

  1. 後藤秀実：全身疾患と消化管．内科学 第11版，朝倉書店，2017; 1019–1025.

  2. 梅野淳嗣，松本主之：膠原病と消化管病変．胃と腸，2012; 47: 818.

  3. Forbes A, Marie I: Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford), 2009; 48: iii36–39.

  4. Kirby DF, Chatterjee S: Evaluation and management of gastrointestinal manifestations in scleroderma. Curr Opin Rheumatol, 2014; 26: 621–629.

  5. 全身性強皮症の診断基準・重症度分類・診療ガイドライン．日本皮膚科学会雑誌，2016; 126: 1831–1896.

  6. Richard N, Hudson M, et al: Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. Rheumatology (Oxford), 2019; 58: 636–644.

  7. Santosa A, Tan CS, et al: Lung and gastrointestinal complications are leading causes of death in SCORE, a multi–ethnic Singapore systemic sclerosis cohort. Scand J Rheumatol, 2016; 45: 499–506.

  8. Ebert EC, Hagspiel KD: Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol, 2011; 45: 436–441.

  9. 前畠裕司，江崎幹宏，他：血管炎による消化管病変の臨床診断　全身性エリテマトーデス．胃と腸，2015; 50: 1397–1405.

  10. Teramoto J, Takahashi Y, et al: Systemic lupus erythematosus with a giant rectal ulcer and perforation. Intern Med, 1999; 38: 643–649.

  11. Jennette JC, Falk RJ, et al: 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum, 2013; 65: 1–11.

  12. Ebert EC, Hagspiel KD, et al: Gastrointestinal involvement in polyarteritis nodosa. Clin Gastroenterol Hepatol, 2008; 6: 960–966.

  13. 松本啓志，村尾高久，他：血管炎による消化管病変の臨床診断―結節性多発動脈炎．胃と腸，2015; 50: 1389–1396.

  14. Levine SM, Hellmann DB, et al: Gastrointestinal involvement in polyarteritis nodosa (1986–2000): presentation and outcomes in 24 patients. Am J Med, 2002; 112: 386–391.

  15. 青柳邦彦，中村昌太郎，他：Churg–Strauss症候群．胃と腸，2003; 38: 567–572.

  16. Pagnoux C, Guilpain P, et al: Churg–Strauss syndrome. Curr Opin Rheumatol, 2007; 19: 25–32.

  17. Lanham JG, Elkon KB, et al: Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg–Strauss syndrome. Medicine (Baltimore), 1984; 63: 65–81.

  18. Itawaki A, Okada M, et al: Eosinophilic granulomatosis with polyangiitis initially diagnosed as eosinophilic gastroenteritis. Intern Med, 2020; 59: 1029–1033.

  19. 岡本康治，蔵原晃一，他：血管炎による消化管病変の臨床診断―好酸球性多発血管炎性肉芽腫症 (Churg–Strauss症候群)．胃と腸，2015; 50: 1372–1380.

  20. 江崎幹宏，梅野淳嗣，他：血管炎による消化管病変の臨床診断―IgA血管炎 (Schönlein–Henoch紫斑病)．胃と腸，2015; 50: 1363–1371.

  21. Esaki M, Matsumoto T, et al: GI Involvement in Henoch–Schönlein Purpura. Gastrointest Endosc, 2002; 56: 920–923.

  22. 江崎幹宏，松本主之，他：Schönlein–Henoch紫斑病による十二指腸病変の特徴．胃と腸，2002; 37: 791–800.

  23. Ebert EC, Hagspiel KD: Gastrointestinal and hepatic manifestations of rheumatoid arthritis. Dig Dis Sci, 2011; 56: 295–302.

  24. Mizokami Y, Oda K, et al: Vonoprazan prevents ulcer recurrence during long–term NSAID therapy: randomised, lansoprazole–controlled non–inferiority and single–blind extension study. Gut, 2018; 67: 1042–1051.

  25. Watanabe T, Tanigawa T, et al: Anti–tumour necrosis factor agents reduce non–steroidal anti–inflammatory drug–induced small bowel injury in rheumatoid arthritis patients. Gut, 2014; 63: 409–414.

  26. Okuda Y, Yamada T, et al: First Nationwide Survey of 199 Patients with Amyloid A Amyloidosis in Japan. Intern Med, 2018; 57: 3351–3355.

  27. Kuroda T, Tanabe N, et al: Comparison of gastroduodenal, renal and abdominal fat biopsies for diagnosing amyloidosis in rheumatoid arthritis. Clin Rheumatol, 2002; 21: 123–128.

  28. Kobayashi H, Tada S, et al: Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol, 1996; 35: 44–49.

  29. Shimada Y, Tosa H: A gastrointestinal endoscopic study on secondary amyloidosis complicating rheumatoid arthritis. Dig Endosc, 1992; 4: 37–42.

  30. Genta MS, Genta RM, et al: Systemic rheumatoid vasculitis: a review. Semin Arthr Rheum, 2006; 36: 88–98.

  31. Scott DG, Bacon PA, et al: Systemic rheumatoid vasculitis: a clinical and laboratory study of 50 cases. Medicine, 1981; 60: 288–297.

  32. Geirsson AJ, Sturfelt G, et al: Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis, 1987; 46: 727–733.

  33. Babian M, Nasef S, et al: Gastrointestinal infarction as a manifestation of rheumatoid vasculitis. Am J Gastroenterol, 1998; 93: 119–120.

  34. 厚生労働科学研究難治性疾患克服研究事業べーチェット病に関する調査研究班：腸管ベーチェット病診療ガイドライン平成21年度案～コンセンサス・ステートメントに基づく～，2010．

  35. Hisamatsu T, Ueno F, et al: The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti–TNFα monoclonal antibodies. J Gastroenterol, 2014; 49: 156–162.

  36. Yi SW, Cheon JH, et al: The prevalence and clinical characteristics of esophageal involvement in patients with Behçet’s disease: a single center experience in Korea. J Korean Med Sci, 2009; 24: 52–56.

  37. Chung MJ, Cheon JH, et al: Response rates to medical treatments and long-term clinical outcomes of nonsurgical patients with intestinal Behçet disease. J Clin Gastroenterol, 2010; 44: e116–122.

  38. Tanida S, Inoue N, et al: Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease. Clin Gastroenterol Hepatol, 2015; 13: 940–948.

  39. Hibi T, Hirohata S, et al: Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open–label, single-arm phase 3 study. Medicine (Baltimore), 2016; 95: e3863.

  40. Sun XM, Tan JC, et al: Association between diabetes mellitus and gastroesophageal reflux disease: A meta–analysis. World J Gastroenterol, 2015; 21: 3085–3092.

  41. Phillips LK, Deane AM, et al: Gastric emptying and glycaemia in health and diabetes mellitus. Nat Rev Endocrinol, 2015; 11: 112–128.

  42. Khoshbaten M, Madad L, et al: Gastrointestinal signs and symptoms among persons with diabetes mellitus. Gastroenterol Hepatol Bed Bench, 2011; 4: 219–223.

  43. 山田正仁：厚生労働科学研究費補助金 難治性疾患克服研究事業アミロイドーシスに関する調査研究班：アミロイドーシス診療ガイドライン2010，2010.

  44. Kobayashi H, Tada S, et al: Secondary amyloidosis in patients with rheumatoid arthritis: diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol, 1996; 35: 44–49.

  45. 難病情報センター：ポルフィリン症．https://www.nanbyou.or.jp/entry/5546

  46. Notsu T, Adachi K, et al: Prevalence of autoimmune gastritis in individuals undergoing medical checkups in Japan. Intern Med, 2019; 58: 1817–1823.

  47. 武永　強，山本信彦，他：悪性リンパ腫の消化管病変に関する検討．Gastroenterol Endosc, 1988; 30: 2218–2224.

  48. 平田一郎，溝口良順，他：全身性悪性リンパ腫の消化管病変一画像診断を中心に．胃と腸，2014; 49: 795–809.

  49. Shovlin CL, Guttmacher AE, et al: Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu–Osler–Weber syndrome). Am J Med Genet, 2000; 91: 66–67.

  50. 田中心和，坂口和彦，他：アルゴンプラズマ凝固療法がOsler–Rendu–Weber病の消化管病変に対して有効であった1例．Gatroenterol Endosc, 2006; 48: 31–36.

  51. 川口　実：神経系疾患　Cushing潰瘍．胃と腸，2003; 38: 501–505.

  52. Hatipoglu E, Caglar AS, et al: Peptic ulcer disease in endogenous hypercortisolism: myth or reality? Endocrine, 2015; 50: 489–495.

  53. 新井勝大：原発性免疫不全症に伴う腸炎．IBD research，2018; 12: 104–111.

  54. Ferrara JL, Deeg HJ: Graft–versus–host disease. N Engl J Med, 1991; 324: 667–674.

  55. Ferrara JL, Levine JE, et al: Graft–versus–host disease. Lancet, 2009; 373: 1550–1561.

  56. McDonald GB, Shulman HM, et al: Intestinal and hepatic complications of human bone marrow transplantation. Part I. Gastroenterology, 1986; 90: 460–477.

  57. Collins M, Soularue E, et al: Management of patients with immune checkpoint inhibitor–induced enterocolitis: A systematic review. Clin Gastroenterol Hepatol, 2020; 18: 1393–1403.

  58. 鈴木修司，近藤浩史，他：非閉塞性腸管虚血 (non–occulusive mesenteric ischemia: NOMI) の診断と治療．日本腹部救急医学会雑誌，2015; 35: 177–185.

  59. Okada M, Okada K: Exfoliative esophagitis and esophageal ulcer induced by dabigatran. Endoscopy, 2012; 44: E23–24.